CRBP
Price
$7.40
Change
-$0.62 (-7.73%)
Updated
Jun 27 closing price
Capitalization
91.65M
SKYE
Price
$4.11
Change
-$0.14 (-3.29%)
Updated
Jun 27 closing price
Capitalization
128.62M
Interact to see
Advertisement

CRBP vs SKYE

Header iconCRBP vs SKYE Comparison
Open Charts CRBP vs SKYEBanner chart's image
Corbus Pharmaceuticals Holdings
Price$7.40
Change-$0.62 (-7.73%)
Volume$1.39M
Capitalization91.65M
Skye Bioscience
Price$4.11
Change-$0.14 (-3.29%)
Volume$7.49M
Capitalization128.62M
CRBP vs SKYE Comparison Chart in %
Loading...
CRBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SKYE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRBP vs. SKYE commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRBP is a Hold and SKYE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (CRBP: $7.40 vs. SKYE: $4.11)
Brand notoriety: CRBP and SKYE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRBP: 865% vs. SKYE: 811%
Market capitalization -- CRBP: $91.65M vs. SKYE: $128.62M
CRBP [@Biotechnology] is valued at $91.65M. SKYE’s [@Biotechnology] market capitalization is $128.62M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRBP’s FA Score shows that 0 FA rating(s) are green whileSKYE’s FA Score has 0 green FA rating(s).

  • CRBP’s FA Score: 0 green, 5 red.
  • SKYE’s FA Score: 0 green, 5 red.
According to our system of comparison, SKYE is a better buy in the long-term than CRBP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRBP’s TA Score shows that 3 TA indicator(s) are bullish while SKYE’s TA Score has 4 bullish TA indicator(s).

  • CRBP’s TA Score: 3 bullish, 5 bearish.
  • SKYE’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, SKYE is a better buy in the short-term than CRBP.

Price Growth

CRBP (@Biotechnology) experienced а -10.19% price change this week, while SKYE (@Biotechnology) price change was +90.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SKYE($129M) has a higher market cap than CRBP($91.7M). SKYE YTD gains are higher at: 45.230 vs. CRBP (-37.288). SKYE has higher annual earnings (EBITDA): -31.66M vs. CRBP (-48.74M). CRBP has more cash in the bank: 133M vs. SKYE (59.2M). SKYE has less debt than CRBP: SKYE (412K) vs CRBP (2.86M). CRBP (0) and SKYE (0) have equivalent revenues.
CRBPSKYECRBP / SKYE
Capitalization91.7M129M71%
EBITDA-48.74M-31.66M154%
Gain YTD-37.28845.230-82%
P/E RatioN/A3.57-
Revenue00-
Total Cash133M59.2M225%
Total Debt2.86M412K693%
FUNDAMENTALS RATINGS
CRBP vs SKYE: Fundamental Ratings
CRBP
SKYE
OUTLOOK RATING
1..100
5640
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
39
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
6335
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SKYE's Valuation (39) in the null industry is in the same range as CRBP (50) in the Biotechnology industry. This means that SKYE’s stock grew similarly to CRBP’s over the last 12 months.

SKYE's Profit vs Risk Rating (100) in the null industry is in the same range as CRBP (100) in the Biotechnology industry. This means that SKYE’s stock grew similarly to CRBP’s over the last 12 months.

SKYE's SMR Rating (97) in the null industry is in the same range as CRBP (97) in the Biotechnology industry. This means that SKYE’s stock grew similarly to CRBP’s over the last 12 months.

SKYE's Price Growth Rating (35) in the null industry is in the same range as CRBP (63) in the Biotechnology industry. This means that SKYE’s stock grew similarly to CRBP’s over the last 12 months.

SKYE's P/E Growth Rating (98) in the null industry is in the same range as CRBP (100) in the Biotechnology industry. This means that SKYE’s stock grew similarly to CRBP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRBPSKYE
RSI
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
88%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
86%
Advances
ODDS (%)
N/A
Bullish Trend 4 days ago
86%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
CRBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SKYE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BVRDF34.15N/A
N/A
BUREAU VERITAS SA
DQWS0.07N/A
N/A
Dswiss Inc
MAYNF3.33N/A
N/A
Mayne Pharma Ltd.
SYANY12.99N/A
N/A
Sydbank A/S
AUMC0.64-0.03
-4.48%
AURYN Mining Corporation

CRBP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRBP has been loosely correlated with SKYE. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CRBP jumps, then SKYE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRBP
1D Price
Change %
CRBP100%
-7.73%
SKYE - CRBP
46%
Loosely correlated
-3.29%
FBIO - CRBP
37%
Loosely correlated
N/A
STOK - CRBP
36%
Loosely correlated
-1.77%
APLS - CRBP
34%
Loosely correlated
-5.27%
PMCB - CRBP
31%
Poorly correlated
-1.90%
More

SKYE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SKYE has been loosely correlated with CRBP. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if SKYE jumps, then CRBP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SKYE
1D Price
Change %
SKYE100%
-3.29%
CRBP - SKYE
46%
Loosely correlated
-7.73%
JANX - SKYE
41%
Loosely correlated
-1.57%
OVID - SKYE
36%
Loosely correlated
-11.95%
VKTX - SKYE
34%
Loosely correlated
-5.86%
ARWR - SKYE
33%
Loosely correlated
+0.06%
More